Ivabradine Eg

Active Ingredient:: Ivabradine Hydrochloride
Origin:: EU

Ivabradine Eg (Ivabradine Hydrochloride)

Q: What conditions is Ivabradine Eg used for?

Ivabradine Eg contains ivabradine hydrochloride, which is indicated to lower heart rate in adults with chronic heart failure and stable angina pectoris, helping to improve symptoms and reduce the risk of hospitalization.

Q: How does ivabradine work to lower heart rate?

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, slowing the spontaneous electrical activity that drives heartbeats. This reduces heart rate without affecting the strength of cardiac contraction or blood pressure.

Q: What is the usual dose of Ivabradine Eg?

The dose of ivabradine is individualized by the prescribing clinician based on the patient’s clinical condition, heart‑rate targets, and tolerance. The prescriber determines the appropriate regimen.

Q: Is Ivabradine Eg safe during pregnancy or breastfeeding?

Ivabradine should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate the risk‑benefit profile before prescribing.

Q: How do I order Ivabradine Eg from GNH India?

To request Ivabradine Eg, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does ivabradine compare with beta‑blockers?

Both ivabradine and beta‑blockers lower heart rate, but ivabradine acts specifically on the sinoatrial node’s If current without affecting contractility or blood pressure, whereas beta‑blockers also reduce myocardial contractility and have broader cardiovascular effects.

Q: What are the storage requirements for Ivabradine Eg?

Store Ivabradine Eg tablets at temperatures below 25 °C in the original container, protecting them from moisture and direct sunlight to maintain stability.

Q: How is Ivabradine Eg administered?

Ivabradine Eg is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed, following the prescriber’s instructions regarding timing relative to meals.

Q: What are the most serious risks associated with ivabradine?

Serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and rare visual disturbances that may affect vision. Patients should be monitored for these events, especially when initiating therapy or adjusting doses.

Q: Who should not use Ivabradine Eg?

Ivabradine is contraindicated in patients with severe hypotension, sick sinus syndrome, second‑ or third‑degree atrioventricular block, acute myocardial infarction, or those taking strong CYP3A4 inhibitors without dose adjustment.

Ivabradine Hydrochloride, the active ingredient in Ivabradine Eg, is a heart‑rate‑lowering agent presented as an oral tablet for oral use. It selectively reduces sinus node activity and is employed in the management of chronic heart failure and stable angina in adult patients.
GNH India supplies Ivabradine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Eg Labo Laboratoires Eurogenerics

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine Hydrochloride is used to modulate heart rate in cardiovascular conditions.

Chronic heart failure: reduces heart rate to improve symptoms and decrease hospitalizations.
Stable angina pectoris: lowers heart rate to relieve angina episodes when beta‑blockers are unsuitable.
Inappropriate sinus tachycardia (off‑label): helps control excessive heart rate when other therapies fail.

How It Works

Ivabradine Hydrochloride selectively inhibits the funny (If) current in the sinoatrial node, decreasing spontaneous depolarisation and thereby lowering heart rate without affecting myocardial contractility or blood pressure, which helps improve cardiac efficiency in selected cardiovascular disorders.

Side Effects

Adverse reactions may occur with ivabradine use.

Common Side Effects

Bradycardia: slowed heart rate, may cause fatigue.
Visual disturbances: luminous phenomena (phosphenes).
Headache: mild to moderate intensity.
Dizziness: especially on standing.
Hypertension: occasional increase in blood pressure.
Fatigue: general tiredness.

Serious or Rare Side Effects

Symptomatic bradycardia requiring medical attention.
Atrial fibrillation or other arrhythmias.
Severe hypotension leading to syncope.
Persistent visual impairment or retinal issues.
Allergic reactions: rash, angioedema.
Hepatic dysfunction in rare cases.

Precautions & Warnings

Before initiating ivabradine, consider the following precautions.

Contraindication: severe hypotension or systolic BP <90 mmHg.
Caution: existing sinus node dysfunction or AV block.
Monitor: heart rate regularly, especially after dose changes.
Avoid: concomitant use with strong CYP3A4 inhibitors without dose adjustment.
Pregnancy and lactation: use only if potential benefit justifies potential risk.
Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Ivabradine may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ivabradine levels.
Concomitant bradycardic agents (beta‑blockers, diltiazem, verapamil): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely)

Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly raise plasma concentrations.
Digoxin: monitor for additive effects on cardiac conduction.
Antihypertensives: watch for additive blood‑pressure lowering.
St. John’s wort: may reduce ivabradine exposure, decreasing efficacy.

Frequently Asked Questions

Ivabradine Eg contains ivabradine hydrochloride, which is indicated to lower heart rate in adults with chronic heart failure and stable angina pectoris, helping to improve symptoms and reduce the risk of hospitalization.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, slowing the spontaneous electrical activity that drives heartbeats. This reduces heart rate without affecting the strength of cardiac contraction or blood pressure.

The dose of ivabradine is individualized by the prescribing clinician based on the patient’s clinical condition, heart‑rate targets, and tolerance. The prescriber determines the appropriate regimen.

Ivabradine should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate the risk‑benefit profile before prescribing.

To request Ivabradine Eg, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine acts specifically on the sinoatrial node’s If current without affecting contractility or blood pressure, whereas beta‑blockers also reduce myocardial contractility and have broader cardiovascular effects.

Store Ivabradine Eg tablets at temperatures below 25 °C in the original container, protecting them from moisture and direct sunlight to maintain stability.

Ivabradine Eg is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed, following the prescriber’s instructions regarding timing relative to meals.

Serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and rare visual disturbances that may affect vision. Patients should be monitored for these events, especially when initiating therapy or adjusting doses.

Ivabradine is contraindicated in patients with severe hypotension, sick sinus syndrome, second‑ or third‑degree atrioventricular block, acute myocardial infarction, or those taking strong CYP3A4 inhibitors without dose adjustment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.